Literature DB >> 8841738

Recognition and treatment of unstable angina.

C Brunelli1, P Spallarossa, P Rossettin, S Caponnetto.   

Abstract

Despite the growing number of patients discharged from hospital with a diagnosis of unstable angina, the diagnostic procedures and treatment of unstable angina are still greatly debated, as they have been for patients with myocardial infarction. In recent years the definition and classification of the clinical syndrome of unstable angina has been subjected to numerous proposals by distinguished cardiologists. An attempt to clarify and redefine practical guidelines for different subgroups of patients has been developed and carried out by the US Agency for Health Care Policy and Research (AHCPR). The current medical approach to treatment of patients with unstable angina is discussed in detail, analysing the role of antiplatelet medications, beta-blockers, nitrates, heparin and calcium antagonists. The small subgroup of patients with refractory unstable angina should undergo urgent coronary angiography and revascularisation. Previous and current research on medical treatment with thrombolytic therapy, GPIIb/IIIa platelet receptor blockers and direct thrombin inhibitors is outlined, keeping in mind one of the main aspects of pathophysiology of the disease, that is ongoing thrombus formation. In the future, a more aggressive strategy aimed at normalising the atherogenic lipid profile in this very high risk group of patients should be carried out, based on the positive results of lipid-lowering drug trials both in primary and secondary prevention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841738     DOI: 10.2165/00003495-199652020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  74 in total

1.  Unstable angina. A classification.

Authors:  E Braunwald
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

2.  Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring.

Authors:  C Brunelli; P Spallarossa; G Ghigliotti; P Lantieri; M Iannetti; S Caponnetto
Journal:  Clin Cardiol       Date:  1991-04       Impact factor: 2.882

3.  Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.

Authors:  R M Lidón; P Théroux; M Juneau; B Adelman; J Maraganore
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

Review 4.  Direct thrombin inhibitors in cardiovascular medicine.

Authors:  J Lefkovits; E J Topol
Journal:  Circulation       Date:  1994-09       Impact factor: 29.690

5.  Rebound myocardial ischaemia following abrupt interruption of intravenous nitroglycerin infusion in patients with unstable angina at rest.

Authors:  J Figueras; R Lidon; J Cortadellas
Journal:  Eur Heart J       Date:  1991-03       Impact factor: 29.983

6.  Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Authors:  P Théroux; D Waters; S Qiu; J McCans; P de Guise; M Juneau
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

7.  Nifedipine in unstable angina: a double-blind, randomized trial.

Authors:  G Gerstenblith; P Ouyang; S C Achuff; B H Bulkley; L C Becker; E D Mellits; K L Baughman; J L Weiss; J T Flaherty; C H Kallman; M Llewellyn; M L Weisfeldt
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

8.  Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine.

Authors:  C J Hawkey; K W Somerville; S Marshall
Journal:  Aliment Pharmacol Ther       Date:  1988-06       Impact factor: 8.171

9.  Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

Authors:  L C Wallentin
Journal:  J Am Coll Cardiol       Date:  1991-12       Impact factor: 24.094

10.  Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.

Authors:  G G Neri Serneri; G F Gensini; L Poggesi; F Trotta; P A Modesti; M Boddi; A Ieri; M Margheri; G C Casolo; M Bini
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

View more
  3 in total

Review 1.  Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Authors:  K L Goa; S Noble
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

2.  Management of Acute Ischemic Coronary Syndromes: The Present and Future.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-11       Impact factor: 2.300

Review 3.  Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

Authors:  S Noble; C M Spencer
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.